Primary sources of pelvic serous cancer in patients with endometrial intraepithelial carcinoma

Modern Pathology

Volumn 28, Issue 1, 2015, Pages 118-127

  Jia, Lin ^a,b   Yuan, Zeng ^a,b   Wang, Yiying ^b,c   Cragun, Janiel M ^b   Kong, Beihua ^a   Zheng, Wenxin ^a,b,d  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CELL LINEAGE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; METASTASIS; PELVIC SEROUS CANCER; PELVIS CANCER; SEROUS ENDOMETRIAL INTRAEPITHELIAL CARCINOMA; TUMOR VOLUME; VERY ELDERLY; CARCINOMA IN SITU; CYSTADENOCARCINOMA; DNA MUTATIONAL ANALYSIS; ENDOMETRIUM TUMOR; GENETICS; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MIDDLE AGED; PATHOLOGY; PELVIS TUMOR; POLYMERASE CHAIN REACTION; UTERINE TUBE TUMOR;

AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; CYSTADENOCARCINOMA, SEROUS; DNA MUTATIONAL ANALYSIS; ENDOMETRIAL NEOPLASMS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MIDDLE AGED; PELVIC NEOPLASMS; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84920670945     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.76     Document Type: Article

References (49)

1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA: Cancer J Clin 2014;64:9-29.
2. Jarboe EA, Mutter GL. Endometrial intraepithelial neoplasia. Semin Diagn Pathol 2010;27:215-225.
3. Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol 2000;76:287-290.
4. Fader AN, Drake RD, O'Malley DM, et al. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer 2009;115: 2119-2127.
5. Havrilesky LJ, Secord AA, Bae-Jump V, et al. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol 2007;105:677-682.
6. Zheng WX, Fadare O. Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas. Int J Clin Exp Patho 2012;5:182-186.
7. Zheng W, Xiang L, Fadare O, et al. A proposed model for endometrial serous carcinogenesis. Am J Surg Pathol 2011;35:e1-e14.
8. Fadare O, Zheng WX. Insights into endometrial serous carcinogenesis and progression. Int J Clin Exp Patho 2009;2:411-432.
9. Spiegel GW. Endometrial carcinoma in situ in postmenopausal women. Am J Surg Pathol 1995;19: 417-432.
10. Ambros RA, Sherman ME, Zahn CM, et al. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995;26:1260-1267.
11. Fadare O, Zheng W. Endometrial serous carcinoma (uterine papillary serous carcinoma): precancerous lesions and the theoretical promise of a preventive approach. Am J Cancer Res 2012;2:335-339.
12. Zheng WX, Schwartz PE. Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management. Gynecol Oncol 2005;96:579-582.
13. Wheeler DT, Bell KA, Kurman RJ, et al. Minimal uterine serous carcinoma-diagnosis and clinicopathologic correlation. Am J Surg Pathol 2000;24:797-806.
14. Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 2003;91:463-469.
15. Snyder MJ, Bentley R, Robboy SJ. Transtubal spread of serous adenocarcinoma of the endometrium: an underrecognized mechanism of metastasis. Int J Gynecol Pathol 2006;25:155-160.
16. Roelofsen T, van Kempen LCLT, van der Laak JAWM, et al. Concurrent endometrial intraepithelial carcinoma (EIC) and serous ovarian cancer can EIC be seen as the precursor lesion? Int J Gynecol Cancer 2012;22: 457-464.
17. Yan Z, Hui P. Minimal uterine serous carcinoma with extrauterine tumor of identical morphology: an immunohistochemical study of 13 cases. Appl Immunohistochem Mol Morphol 2010;18:75-79.
18. Jarboe EA, Miron A, Carlson JW, et al. Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance. Int J Gynecol Pathol 2009;28:308-315.
19. Hui P, Kelly M, O'Malley DM, et al. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Mod Pathol 2005;18:75-82.
20. Baergen RN, Warren CD, Isacson C, et al. Early uterine serous carcinoma: clonal origin of extrauterine disease. Int J Gynecol Pathol 2001;20:214-219.
21. Soslow RA, Pirog E, Isacson C. Endometrial intraepithelial carcinoma with associated peritoneal carcinomatosis. Am J Surg Pathol 2000;24:726-732.
22. Kupryjanczyk J, Thor AD, Beauchamp R, et al. Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease. Mod Pathol 1996;9:166-173.
23. Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994;54:264-268.
24. Tashiro H, Isacson C, Levine R, et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177-185.
25. Zhang X, Liang SX, Jia L, et al. Molecular identification of 'latent precancers' for endometrial serous carcinoma in benign-appearing endometrium. Am J Pathol 2009;174:2000-2006.
26. Jia L, Liu Y, Yi X, et al. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res 2008;14:2263-2269.
27. Hodges KB, Cummings OW, Saxena R, et al. Clonal origin of multifocal hepatocellular carcinoma. Cancer 2010;116:4078-4085.
28. Jones TD, Eble JN, Wang M, et al. Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation. Cancer 2005;104:1195-1203.
29. Li J, Fadare O, Xiang L, et al. Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. J Hematol Oncol 2012;5:8.
30. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006;30:230-236.
31. Przybycin CG, Kurman RJ, Ronnett BM, et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010;34:1407-1416.
32. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007;31:161-169.
33. Zheng WX, Sung CJ, Cao PQ, et al. Early occurrence and prognostic significance of p53 alteration in primary carcinoma of the fallopian tube. Gynecol Oncol 1997;64:38-48.
34. Zheng WX, Cao PQ, Zheng M, et al. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 1996;61:167-174.
35. Zheng WX, Khurana R, Farahmand S, et al. p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma-precursor of uterine papillary serous carcinoma. Am J Surg Pathol 1998;22:1463-1473.
36. Kobel M, Reuss A, du Bois A, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 2010;222:191-198.
37. Salvador S, Gilks B, Kobel M, et al. The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer 2009;19:58-64.
38. Crum CP. Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol 2009;3:165-170.
39. Massuger L, Roelofsen T, van Ham M, et al. The origin of serous ovarian cancer may be found in the uterus: a novel hypothesis. Med Hypotheses 2010;74:859-861.
40. Jarboe EA, Folkins AK, Drapkin R, et al. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology 2008;53: 127-138.
41. Young RH, Scully RE. Invasive adenocarcinoma and related tumors of the uterine cervix. Semin Diagn Pathol 1990;7:205-227.
42. Gilks CB, Clement PB. Papillary serous adenocarcinoma of the uterine cervix: a report of three cases. Mod Pathol 1992;5:426-431.
43. Zhou C, Gilks CB, Hayes M, et al. Papillary serous carcinoma of the uterine cervix- A clinicopathologic study of 17 cases. Am J Surg Pathol 1998;22:113-120.
44. Harris CC 1995) Deichmann lecture-p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment. Toxicol Lett 1995;82-3:1-7.
45. Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 2011;42:918-931.
46. Cheng L, Jones TD, McCarthy RP, et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol 2005;166:1533-1539.
47. Horn LC, Kafkova S, Leonhardt K, et al. Serous tubal in situ carcinoma (STIC) in primary peritoneal serous carcinomas. Int J Gynecol Pathol 2013;32:339-344.
48. Horn LC, Leonhardt K, Kafkova S, et al. Serous tubal in situ carcinoma (STIC) in tubal and primary peritoneal carcinomas. Virchows Arch 2012;461: S308-S309.
49. Folkins AK, Jarboe EA, Roh MH, et al. Precursors to pelvic serous carcinoma and their clinical implications. Gynecol Oncol 2009;113:391-396.